🇯🇵 日本語 🇺🇸 English
3,813 companies 10,012 AI summaries 7,617 risk analyses 3,719 growth scores Register free — watchlist & alerts →
EDINET 4507 Positive Risk Analyzed 📈 Growth 8/10

Shionogi & Co.,Ltd.

Extraordinary Report ／ 2026-10-06 15:38

Covers EDINET statutory filings (TDNET timely disclosures / earnings flashes are not included).

M&AM&A/AllianceNew ProductNew MarketR&D
AI Summary 2026-10-06 15:45

Shionogi acquires IntraBio Inc. for $2.0B to expand rare disease portfolio. Acquisition includes AQNEURSA with world-first FDA approval as A-T treatment and intellectual property in rare neurological diseases, leveraging existing RADICAVA® ALS platform in US.

KEY POINTS
  • Acquisition of IntraBio Inc. approved for $2.0B (October 5, 2026 board resolution)
  • AQNEURSA received world-first FDA approval for Ataxia-Telangiectasia (A-T) treatment (September 18, 2026)
  • Combines IntraBio's rare neurological disease expertise with Shionogi's US RADICAVA® ALS platform for accelerated rare disease growth
📊 Revenue
N/A
💰 Operating profit
N/A
🔮 Outlook
Not stated
📈 Growth outlook 📈 Growth 8/10
Strategic acceleration of rare disease business expansion. AQNEURSA approvals (NPC, A-T) combined with development pipeline (Fragile X, Jordan syndrome, Pompe disease) expected to drive multi-product rare disease sales growth and R&D pipeline advancement.
Growth drivers
  • AQNEURSA (A-T therapy) commercial launch in US and regulatory applications in Europe
  • Acquisition of IntraBio's rare disease expertise and R&D talent to accelerate pipeline development
  • Leverage existing RADICAVA® US commercial infrastructure and physician relationships for AQNEURSA market penetration
  • Advancement of multiple rare disease programs (Fragile X syndrome, Jordan syndrome, Pompe disease)
Risk and growth scores and tags are AI-generated estimates from analyzing the disclosure. They are not guarantees of fact, nor investment advice or recommendations. Make investment decisions at your own discretion.
⚠️ Extracted Risk Factors
CategoryDescriptionScoreNew
M&A Risk Integration risks including organizational alignment, talent retention, and realization of expected synergies. $2.0B acquisition value recovery uncertainty. 8/10
Technology Risk Clinical trial failure or regulatory approval delays for AQNEURSA and pipeline compounds in rare indications. Patient recruitment and trial execution challenges in small populations. 7/10 NEW
Market Risk Limited patient populations in rare diseases constraining sales scale and growth rates. Competitive entry risk from larger pharma in rare disease segment. 6/10 NEW
Foreign Exchange Risk USD/JPY exchange rate exposure on $2.0B acquisition payment and future USD-denominated IntraBio cash flows impacting consolidated earnings. 6/10
Regulatory Risk European regulatory approval delays or rejection for AQNEURSA A-T indication. Reimbursement policy uncertainty across healthcare systems. 5/10 NEW
Competitive Risk Intensifying competitive pressure in rare neurological disease therapeutics. Risk of AQNEURSA market share erosion from rival treatments. 5/10 NEW
8/10 M&A Risk
Integration risks including organizational alignment, talent retention, and realization of expected synergies. $2.0B acquisition value recovery uncertainty.
7/10 NEW Technology Risk
Clinical trial failure or regulatory approval delays for AQNEURSA and pipeline compounds in rare indications. Patient recruitment and trial execution challenges in small populations.
6/10 NEW Market Risk
Limited patient populations in rare diseases constraining sales scale and growth rates. Competitive entry risk from larger pharma in rare disease segment.
6/10 Foreign Exchange Risk
USD/JPY exchange rate exposure on $2.0B acquisition payment and future USD-denominated IntraBio cash flows impacting consolidated earnings.
5/10 NEW Regulatory Risk
European regulatory approval delays or rejection for AQNEURSA A-T indication. Reimbursement policy uncertainty across healthcare systems.
5/10 NEW Competitive Risk
Intensifying competitive pressure in rare neurological disease therapeutics. Risk of AQNEURSA market share erosion from rival treatments.
X LinkedIn Threads Bluesky Facebook
Track Japanese disclosures with JSIGNAL

AI summaries, risk & growth analysis, watchlist alerts and a screener for every Japanese listed company.

Start free — 30-day trial Login